What is the focus of your current research and what aspects are you interested in?
Currently, my research centres on advancing translational projects from the lab to the clinic, with a primary focus on developing iPSC-derived allogeneic macrophages as a scalable, efficacious, and GMP-compliant cellular therapy against solid tumors. Complementing this, I’m also developing robust alternative pipelines of macrophage-based therapies to address other diseases with high unmet needs.
 
Please finish the following sentence: “SaxoCell is for me...”
Empowering early-career scientists like me to drive high-impact translational research that accelerates cell and gene therapy advancements across Saxony and beyond.

What advice would you give to someone starting out in your profession?
Build practical skills, let setbacks fuel your progress, sharpen your mind, stay curious, passionate and determined.

Join Dr. Thomas Fox to explore how CRISPR-based genome editing and in vivo T-cell programming are advancing next-generation therapies for cancer and immune disorders in this CTGCT Science Talks webinar. Teams webinar Link

The programme of the BioBusiness Summer School is a balance between theoretical sessions focusing on key knowledge of main business topics and interactive sessions with business leaders giving you their insights in the world of Life Sciences companies.

The National Gene and Cell Therapy Registry Germany (nGCT-R) collects real-world data on innovative gene and cell therapies. It aims to improve evidence on their safety and effectiveness. The initiative is backed by leading medical institutions to support research and patient care.

Researchers highlight the emerging potential of in vivo immune cell engineering approaches to complement traditional ex vivo methods, outlining progress, enabling technologies, and key challenges as the field pushes forward in cancer immunotherapy.

CAR-T therapies have become one of the most promising advances in modern oncology. But researchers are already working on improved versions designed to enhance safety and durability. A recent BBC report on a new CAR-T approach for leukemia highlights how these next-generation therapies could extend remission and reshape the future of cell-based cancer treatment.

CAR-T therapies may soon move beyond oncology. Researchers in Erlangen report encouraging results in patients with severe autoimmune diseases - raising the possibility of long-term remission after a single treatment.